Clinical trials are currently being offered at the University of Alabama at Birmingham.
Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of antigen presentation. In this study, Cabozantinib (VEGF inhibitor) and Dostarlimab (immunotherapeutic drug) will be administered as a combination to patients with recurrent gynecologic carcinosarcoma.
Anna Wilbanks, MSN, RN, WHNP-BC
Research Nurse Manager, GYN Oncology Clinical Trials
O’Neal Comprehensive Cancer Center
UAB | The University of Alabama at Birmingham
1700 6th Avenue South, Suite 10100, 10th Fl WIC | Birmingham, AL 35233
O: 205.934.6454 | F: 205-975-9769 | E: firstname.lastname@example.org